Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $9.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Monday, February 24th. Morgan Stanley reduced their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Up 1.0 %

Invivyd stock opened at $1.06 on Wednesday. The firm has a 50 day moving average of $0.90 and a 200 day moving average of $0.87. The firm has a market capitalization of $126.79 million, a price-to-earnings ratio of -0.54 and a beta of 0.61. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the transaction, the director now directly owns 3,170,231 shares in the company, valued at $1,521,710.88. This represents a 2.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 816,466 shares of company stock worth $423,214 in the last three months. 17.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. Proficio Capital Partners LLC bought a new position in shares of Invivyd during the 3rd quarter valued at approximately $27,000. Jane Street Group LLC boosted its position in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC boosted its position in shares of Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Invivyd during the 4th quarter valued at approximately $74,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.